222 related articles for article (PubMed ID: 20740607)
1. Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs.
Ungar WJ; Costa V; Hancock-Howard R; Feldman BM; Laxer RM
Arthritis Care Res (Hoboken); 2011 Jan; 63(1):111-9. PubMed ID: 20740607
[TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
3. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.
Liu Y; Wu EQ; Bensimon AG; Fan CP; Bao Y; Ganguli A; Yang M; Cifaldi M; Mulani P
Adv Ther; 2012 Jul; 29(7):620-34. PubMed ID: 22843208
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
Prince FH; Twilt M; ten Cate R; van Rossum MA; Armbrust W; Hoppenreijs EP; van Santen-Hoeufft M; Koopman-Keemink Y; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2009 May; 68(5):635-41. PubMed ID: 18413443
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Maetzel A; Strand V; Tugwell P; Wells G; Bombardier C
Arthritis Rheum; 2002 Dec; 47(6):655-61. PubMed ID: 12522841
[TBL] [Abstract][Full Text] [Related]
6. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial.
Tynjälä P; Vähäsalo P; Tarkiainen M; Kröger L; Aalto K; Malin M; Putto-Laurila A; Honkanen V; Lahdenne P
Ann Rheum Dis; 2011 Sep; 70(9):1605-12. PubMed ID: 21623000
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis.
Ruperto N; Lovell DJ; Quartier P; Paz E; Rubio-Pérez N; Silva CA; Abud-Mendoza C; Burgos-Vargas R; Gerloni V; Melo-Gomes JA; Saad-Magalhães C; Chavez-Corrales J; Huemer C; Kivitz A; Blanco FJ; Foeldvari I; Hofer M; Horneff G; Huppertz HI; Job-Deslandre C; Loy A; Minden K; Punaro M; Nunez AF; Sigal LH; Block AJ; Nys M; Martini A; Giannini EH;
Arthritis Rheum; 2010 Jun; 62(6):1792-802. PubMed ID: 20191582
[TBL] [Abstract][Full Text] [Related]
8. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis.
Silverman E; Spiegel L; Hawkins D; Petty R; Goldsmith D; Schanberg L; Duffy C; Howard P; Strand V
Arthritis Rheum; 2005 Feb; 52(2):554-62. PubMed ID: 15693001
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
Horneff G; De Bock F; Foeldvari I; Girschick HJ; Michels H; Moebius D; Schmeling H;
Ann Rheum Dis; 2009 Apr; 68(4):519-25. PubMed ID: 18413440
[TBL] [Abstract][Full Text] [Related]
10. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review.
Ungar WJ; Costa V; Burnett HF; Feldman BM; Laxer RM
Semin Arthritis Rheum; 2013 Jun; 42(6):597-618. PubMed ID: 23337074
[TBL] [Abstract][Full Text] [Related]
11. Associations between the American College of Rheumatology pediatric response measures and the continuous measures of disease activity used in adult rheumatoid arthritis: a secondary analysis of clinical trial data from children with polyarticular-course juvenile idiopathic arthritis.
Ringold S; Chon Y; Singer NG
Arthritis Rheum; 2009 Dec; 60(12):3776-83. PubMed ID: 19950286
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment.
van Rossum MA; van Soesbergen RM; Boers M; Zwinderman AH; Fiselier TJ; Franssen MJ; ten Cate R; van Suijlekom-Smit LW; Wulffraat NM; van Luijk WH; Oostveen JC; Kuis W; Dijkmans BA;
Ann Rheum Dis; 2007 Nov; 66(11):1518-24. PubMed ID: 17491099
[TBL] [Abstract][Full Text] [Related]
13. Update on biologics in juvenile idiopathic arthritis.
Ilowite NT
Curr Opin Rheumatol; 2008 Sep; 20(5):613-8. PubMed ID: 18698187
[TBL] [Abstract][Full Text] [Related]
14. Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis.
Bojke L; Epstein D; Craig D; Rodgers M; Woolacott N; Yang H; Sculpher M
Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv39-iv47. PubMed ID: 21859705
[TBL] [Abstract][Full Text] [Related]
15. A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis.
Choi HK; Seeger JD; Kuntz KM
J Rheumatol; 2002 Jun; 29(6):1156-65. PubMed ID: 12064828
[TBL] [Abstract][Full Text] [Related]
16. Update on biologicals for treatment of juvenile idiopathic arthritis.
Horneff G
Expert Opin Biol Ther; 2013 Mar; 13(3):361-76. PubMed ID: 23289865
[TBL] [Abstract][Full Text] [Related]
17. An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register.
Prince FH; de Bekker-Grob EW; Twilt M; van Rossum MA; Hoppenreijs EP; ten Cate R; Koopman-Keemink Y; Gorter SL; Raat H; van Suijlekom-Smit LW
Rheumatology (Oxford); 2011 Jun; 50(6):1131-6. PubMed ID: 21278067
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
[TBL] [Abstract][Full Text] [Related]
19. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis.
Choi HK; Seeger JD; Kuntz KM
Arthritis Rheum; 2000 Oct; 43(10):2316-27. PubMed ID: 11037892
[TBL] [Abstract][Full Text] [Related]
20. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
